Cutaneous HIV-associated Kaposi sarcoma: a potential setting for management by clinical observation
| Autor: | Philip R. Cohen, Ryan R Riahi, Surget V Beatrous, Stratton B Grisoli |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty business.industry Fulminant AIDS-Related Opportunistic Infections Human immunodeficiency virus (HIV) virus diseases Dermatology General Medicine Disease medicine.disease_cause medicine.disease Malignancy Antiretroviral therapy 03 medical and health sciences 030104 developmental biology Immune system Internal medicine Medicine acquired immunodeficiency syndrome cutaneous HAART highly active anti-retroviral treatment HIV human immunodeficiency virus immune immunosuppression Kaposi KS renal transplant sarcoma Sarcoma business |
| Zdroj: | Beatrous, Surget V; Grisoli, Stratton B; Riahi, Ryan R; & Cohen, Philip R. (2017). Cutaneous HIV-associated Kaposi sarcoma: a potential setting for management by clinical observation. Dermatology Online Journal, 23(6). Retrieved from: http://www.escholarship.org/uc/item/50k6p4zp |
| ISSN: | 1087-2108 |
| DOI: | 10.5070/d3236035374 |
| Popis: | Kaposi sarcoma (KS) is a malignancy of viral etiology whose course ranges from cutaneous limited lesions to fulminant disease with multi-organ involvement. Four clinical variants of the disease exist: classic, endemic, iatrogenic, and epidemic. Iatrogenic and epidemic variants of Kaposi sarcoma develop in the setting of immune suppression. Transplant recipients who develop iatrogenic KS typically demonstrate improvement of lesions following de-escalation of immunosuppressive therapy. Similarly, HIV-infected patients who begin highly active antiretroviral therapy (HAART) experience immune reconstitution, which can induce KS regression. We describe two patients with varying clinical outcomes of cutaneous-limited HIV-associated KS after immune reconstitution with HAART. We propose that immune reconstitution with HAART, followed by clinical and radiographic surveillance for disease progression, may be an appropriate initial management strategy for limited cutaneous HIV-associated KS. In patients with more extensive disease at presentation or failure of HAART alone, antineoplastic therapy should be instituted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|